Lipella Pharmaceuticals - Chapter 11 Bankruptcy Filing Disclosure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 30, 2026

Lipella Pharmaceuticals Inc.

(Exact name of registrant as specified in
its charter)

| Delaware | | 001-41575 | | 20-2388040 |
| (State or other jurisdiction
of incorporation) | | (Commission File Number) | | (IRS Employer
Identification No.) |

| 7800 Susquehanna St., Suite
505

Pittsburgh, PA | | 15208 |
| (Address of registrant’s principal executive office) | | (Zip code) |

Registrant’s telephone number, including
area code: (412) 894-1853

Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):

| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Securities registered pursuant to Section
12(b) of the Act: None.

Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.03 Bankruptcy or Receivership

On [Filing Date], [Company Name,
Inc.] (the “Company”) and certain of its subsidiaries (collectively, the “Debtors”) filed voluntary
petitions for relief under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the
Western District of Pennsylvania (the “Bankruptcy Court”).

Cautionary Note Regarding Chapter 11
Case

The Company cautions that trading in the
Company’s common stock during the pendency of the Chapter 11 case is highly speculative and poses substantial risks. Trading
prices for the Company’s common stock may bear little or no relationship to the actual recovery, if any, by holders of the
Company’s common stock in the Chapter 11 Cases.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

| Exhibit No. | **** | Description |
| 99.1 | | Press Release, dated March 30, 2026 |
| 104 | | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| Date: March 30, 2026 | Lipella Pharmaceuticals Inc. | | |
| | | | |
| | By: | /s/ Jonathan Kaufman | |
| | | Name: Jonathan Kaufman

Title: Chief Executive Officer | |